Nutriband, the Florida-based pharma company of presidential hopeful Gareth Sheridan, reported revenue of $1.28 million (€1.1 million) for the six months ended in July but is still loss-making. The company, which develops a transdermal patch for the safe delivery of fentanyl and is listed on the Nasdaq, saw revenue jump up from $851,362 for the same period the previous year, according to documents filed with the SEC. Current revenue comes from the sale of existing contract services and consumer patch and tape products. While revenue was up, it is still a loss-making company with net losses for that six-month period…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €50.

Subscribe

Cancel at any time.

Are you already a member? .